In recent years, breakthroughs have been made in understanding the molecular biology of PCP, particularly regarding the BRAF V600E mutation, leading to significant advances in targeted therapies and affirming its status as a distinct tumor entity. The gene discussed is BRAF; the disease is pneumocystosis.